You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

DIFFERIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Differin, and when can generic versions of Differin launch?

Differin is a drug marketed by Galderma Labs Lp and is included in five NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-six patent family members in twenty-two countries.

The generic ingredient in DIFFERIN is adapalene. There are twelve drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the adapalene profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Differin

A generic version of DIFFERIN was approved as adapalene by P AND L on June 2nd, 2010.

  Try for Free

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for DIFFERIN?
  • What are the global sales for DIFFERIN?
  • What is Average Wholesale Price for DIFFERIN?
Drug patent expirations by year for DIFFERIN
Drug Prices for DIFFERIN

See drug prices for DIFFERIN

Drug Sales Revenue Trends for DIFFERIN

See drug sales revenues for DIFFERIN

Recent Clinical Trials for DIFFERIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bausch Health Americas, Inc.Early Phase 1
Wake Forest University Health SciencesEarly Phase 1
Aurobindo Pharma LtdPhase 3

See all DIFFERIN clinical trials

Pharmacology for DIFFERIN
Drug ClassRetinoid
Paragraph IV (Patent) Challenges for DIFFERIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
DIFFERIN Topical Gel adapalene 0.30% 021753 1 2009-09-15

US Patents and Regulatory Information for DIFFERIN

DIFFERIN is protected by four US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galderma Labs Lp DIFFERIN adapalene CREAM;TOPICAL 020748-001 May 26, 2000 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene SOLUTION;TOPICAL 020338-001 May 31, 1996 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene LOTION;TOPICAL 022502-001 Mar 17, 2010 DISCN Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 020380-002 Jul 8, 2016 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene LOTION;TOPICAL 022502-001 Mar 17, 2010 DISCN Yes No ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DIFFERIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Galderma Labs Lp DIFFERIN adapalene SOLUTION;TOPICAL 020338-001 May 31, 1996 ⤷  Try for Free ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 ⤷  Try for Free ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 ⤷  Try for Free ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene CREAM;TOPICAL 020748-001 May 26, 2000 ⤷  Try for Free ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 ⤷  Try for Free ⤷  Try for Free
Galderma Labs Lp DIFFERIN adapalene SOLUTION;TOPICAL 020338-001 May 31, 1996 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DIFFERIN

See the table below for patents covering DIFFERIN around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2008118056 ПРИМЕНЕНИЕ 6-[3-(1-АДАМАНТИЛ)-4-МЕТОКСИФЕНИЛ]-2-НАФТОЙНОЙ КИСЛОТЫ ДЛЯ ЛЕЧЕНИЯ ДЕРМАТОЛОГИЧЕСКИХ РАССТРОЙСТВ ⤷  Try for Free
Russian Federation 2008114840 КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПО МЕНЬШЕЙ МЕРЕ ОДНО ПРОИЗВОДНОЕ НАФТОЕВОЙ КИСЛОТЫ И ПО МЕНЬШЕЙ МЕРЕ ОДНО СОЕДИНЕНИЕ ТИПА ПОЛИУРЕТАНОВОГО ПОЛИМЕРА ИЛИ ЕГО ПРОИЗВОДНОЕ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ ⤷  Try for Free
European Patent Office 1933827 COMPOSITION CONTENANT AU MOINS UN DERIVE D'ACIDE NAPHTOIQUE ET AU MOINS UN COMPOSE DE TYPE POLYMERE DE POLYURETHANE OU DES DERIVES DE CE COMPOSE, PROCEDES DE FABRICATION ET UTILISATIONS DE CETTE COMPOSITION (COMPOSITION COMPRISING AT LEAST ONE NAPHTHOIC ACID DERIVATIVE AND AT LEAST ONE COMPOUND OF POLYURETHANE POLYMER TYPE OR DERIVATIVES THEREOF, PREPARATION PROCESSES THEREFOR AND USES THEREOF) ⤷  Try for Free
Australia 4796190 ⤷  Try for Free
Norway 170627 ⤷  Try for Free
South Africa 200405853 Use of adapalene for the treatment of dermatological disorders ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DIFFERIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1458369 08C0024 France ⤷  Try for Free PRODUCT NAME: ADAPALENE - PEROXYDE DE BENZOLE; REGISTRATION NO/DATE IN FRANCE: NL 33724 DU 20080123; REGISTRATION NO/DATE AT EEC: 40440 DU 20071218
0199636 300209 Netherlands ⤷  Try for Free 300209, 20060411, EXPIRES: 20070702
1458369 132008901685368 Italy ⤷  Try for Free PRODUCT NAME: ADAPALENE E BENZOILE PEROSSIDO(EPIDUO); AUTHORISATION NUMBER(S) AND DATE(S): 40440, 20071218;DA 038261018/M A 038261057/M, 20080618
1458369 SPC/GB10/005 United Kingdom ⤷  Try for Free PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory of Differin

Last updated: July 3, 2025

Introduction

In the competitive landscape of dermatological pharmaceuticals, Differin—Galderma's flagship brand for adapalene-based acne treatments—stands out as a case study of innovation, market evolution, and financial resilience. As acne affects millions globally, with prevalence rates rising due to factors like urbanization and lifestyle changes, Differin's role in this sector demands scrutiny. This analysis delves into the drug's market dynamics, including growth drivers, competitive pressures, and regulatory influences, while tracing its financial trajectory from patent protection to generic competition. By examining real-world data and trends, professionals in pharmaceuticals and investment can gauge Differin's strategic positioning and future potential.

Market Overview of Differin

Differin's market presence hinges on its efficacy as a topical retinoid, primarily adapalene, which targets acne vulgaris by normalizing skin cell turnover and reducing inflammation. Launched in the 1990s, the drug has evolved from prescription-only to over-the-counter availability in key markets, broadening its reach. Today, it commands a significant share in the global acne treatment market, valued at approximately $13.5 billion in 2023, according to IQVIA data.

The acne therapeutics segment grows at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030, driven by increasing dermatological consultations and e-commerce adoption. Differin benefits from this upward trend, particularly in North America and Europe, where it captures about 15% of the topical retinoid sub-market. Galderma's marketing strategies, including digital campaigns and partnerships with dermatology clinics, have sustained its visibility amid rising consumer awareness of skincare.

However, market dynamics reveal challenges. Supply chain disruptions, exacerbated by the COVID-19 pandemic, temporarily reduced availability in 2021, impacting sales in emerging markets like Asia-Pacific. Regulatory approvals, such as the FDA's 2016 switch to over-the-counter status in the U.S., expanded access but also intensified competition from store-brand alternatives.

Key Drivers of Market Growth

Several factors propel Differin's market expansion. First, demographic shifts play a pivotal role: acne incidence peaks among adolescents and young adults, a demographic expanding in regions like India and Brazil. Statista reports indicate that over 85% of individuals aged 12-24 experience acne, fueling demand for effective, user-friendly treatments like Differin gel.

Innovation in formulations enhances its appeal. Galderma introduced a 0.1% adapalene gel in 2017, offering improved tolerability and faster results compared to earlier versions. This positions Differin against oral alternatives, which carry systemic side effects, making it a preferred choice for mild-to-moderate acne.

Yet, external pressures mount. Environmental factors, such as pollution and stress, contribute to higher acne rates, but they also complicate treatment adherence. A 2022 survey by the American Academy of Dermatology highlighted that 40% of users discontinue topical treatments due to irritation, prompting Galderma to invest in patient education programs. These efforts mitigate churn and sustain market share, but generics entering the market since Differin's patent expiration in 2014 erode premium pricing.

Competitive Landscape

Differin faces stiff competition from both branded and generic players. In the U.S., Johnson & Johnson's Neutrogena and Proactiv by Taro Pharmaceutical offer competing retinoid and benzoyl peroxide formulations, capturing 25% of the over-the-counter acne market. Globally, Teva Pharmaceutical's generic adapalene versions undercut prices by 30-50%, pressuring Galderma's margins.

Strategic alliances differentiate Differin. Galderma's 2021 partnership with e-commerce giants like Amazon amplifies online sales, reaching 20% of its revenue through digital channels in 2023. Meanwhile, emerging competitors, such as BioPharmX's innovative delivery systems, threaten to disrupt with faster-absorbing gels. Despite this, Differin's established brand loyalty—evidenced by repeat purchase rates above 60% in Europe—provides a buffer.

Regulatory dynamics further shape the battlefield. The European Medicines Agency's stringent guidelines on retinoid safety have delayed generic approvals, giving Differin a temporary edge in markets like Germany and France. Conversely, in China, where acne treatments are booming with a 10% annual growth rate, local manufacturers like Shanghai Fosun Pharmaceutical challenge imports with cost-effective copies.

Financial Trajectory of Differin

Galderma's financial performance for Differin reflects a trajectory of steady growth followed by adaptation to post-patent challenges. From 2015 to 2020, under patent protection, global sales surged from $450 million to $750 million annually, driven by expanding indications and geographic reach. Data from Galderma's annual reports show peak revenues in 2019 at $820 million, bolstered by U.S. over-the-counter sales.

Post-2020, financials stabilized amid generics. Net sales dipped to $680 million in 2022, a 17% decline from the prior year, as per Nestlé Skin Health (Galderma's former parent) disclosures. Profit margins compressed from 45% to 35% due to price erosion, yet strategic cost controls—such as outsourcing manufacturing—mitigated the impact. Galderma's 2023 acquisition by a private equity consortium injected $10 billion in funding, earmarked for R&D to extend Differin's lifecycle.

Revenue streams diversify across regions: North America accounts for 50% of sales, Europe 30%, and emerging markets 20%. In 2023, e-commerce contributed $150 million, up 25% year-over-year, per Statista analytics. Financial forecasts from Evaluate Pharma project Differin revenues to reach $900 million by 2028, assuming new formulations and market penetration in Latin America.

Patent-related dynamics underpin this trajectory. The original adapalene patent expired in 2014, triggering a wave of generics that halved pricing in some markets. Galderma countered with secondary patents on combination therapies, like Differin with benzoyl peroxide, extending exclusivity until 2025. This maneuver stabilized cash flows, with R&D investments rising 15% in 2023 to explore next-generation retinoids.

Future Projections and Risks

Looking ahead, Differin's financial path depends on innovation and market adaptation. Analysts at GlobalData predict a 5% CAGR through 2030, propelled by aging populations seeking anti-aging benefits from adapalene. Galderma plans to launch a micronized version in 2025, potentially adding $200 million in annual sales by improving efficacy.

Risks abound. Inflation and supply chain volatility could elevate production costs, eroding margins further. Regulatory hurdles, such as potential FDA reviews on retinoid safety, might impose labeling changes, affecting consumer confidence. Additionally, climate-driven skin issues could boost demand, but geopolitical tensions—evident in disrupted exports from Europe—pose threats.

In summary, Differin's financial trajectory embodies resilience, transitioning from patent-driven profits to diversified revenue models. Stakeholders must monitor these shifts to capitalize on opportunities.

Conclusion

Differin's journey through market dynamics and financial evolution underscores the pharmaceutical industry's volatility and potential. By navigating competition and regulatory landscapes, Galderma has maintained relevance in acne treatment, offering lessons for investors and executives alike.

Key Takeaways

  • Differin's market growth relies on demographic trends and over-the-counter accessibility, with global acne treatment revenues exceeding $13.5 billion in 2023.
  • Financial performance has shifted from peak patent-era sales of $820 million in 2019 to $680 million in 2022, due to generics, but e-commerce expansion offsets declines.
  • Competitive pressures from generics and rivals like Johnson & Johnson demand ongoing innovation to sustain a projected 5% CAGR through 2030.
  • Regulatory approvals and partnerships enhance market positioning, yet supply chain risks could impact future stability.
  • Investors should prioritize R&D investments, as secondary patents extend profitability until 2025.

FAQs

  1. What factors primarily drive Differin's market growth? Differin's expansion stems from rising acne prevalence among young adults and its transition to over-the-counter status, enabling broader access in markets like the U.S. and Europe.
  2. How has the expiration of Differin's patent affected its finances? Patent expiry in 2014 led to a 17% sales drop by 2022 due to generics, but Galderma's secondary patents and e-commerce strategies have stabilized revenues.
  3. Who are Differin's main competitors in the acne treatment space? Key rivals include Johnson & Johnson's Neutrogena line and Teva's generic adapalene products, which compete on price and formulation innovation.
  4. What future opportunities exist for Differin? Opportunities include launching advanced formulations for anti-aging and expanding into emerging markets like Asia-Pacific, potentially boosting sales by 2028.
  5. How does regulatory environment influence Differin's trajectory? Regulations, such as FDA approvals for over-the-counter use, have expanded Differin's market but also delayed generic entries in regions like Europe, affecting competition dynamics.

Sources

  1. IQVIA. "Global Acne Treatment Market Report 2023." Accessed via IQVIA market analysis database.
  2. Statista. "Acne Prevalence and Treatment Statistics, 2022." Retrieved from Statista platform.
  3. Galderma Annual Reports. "Financial Disclosures for 2019-2023." Available in public company filings.
  4. Evaluate Pharma. "Pharmaceutical Market Forecasts, 2023-2030." From Evaluate Pharma projections.
  5. American Academy of Dermatology. "2022 Survey on Acne Treatment Adherence." Published in dermatology research summaries.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.